Pharma raises its bet on biotech

FromBehind the Money

Start listening View podcast show

Pharma raises its bet on biotech

FromBehind the Money

ratings:

Length:

19 minutes

Released:

Jan 15, 2019

Format:

Podcast episode

Description

In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019. Read more from Sarah at FT.com. For information regarding your data privacy, visit acast.com/privacy

Released:

Jan 15, 2019

Format:

Podcast episode

Titles in the series (100)

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the big business and financial stories of the moment with reporting from Financial Times journalists around the world. Hosted by Aimee Keane.

Skip carousel

The hunt for Fox: Rupert Murdoch built a global media empire across newspaper, television and film companies. Why is now the time for him to sell many of the 21st Century Fox assets? And which media or telecoms giant will scoop them up? With the FT's Matt Garrahan ... by Behind the Money
20 min listen
The $100bn SoftBank vision: The man who built a $100bn fund has wooed investors with his vision for the future. But what is really behind the prowess of SoftBank's Masayoshi Son? With the FT's Arash Massoudi. Read Arash's story here. Review clips: Fox News, CNN,... by Behind the Money
21 min listen
How beauty is beating the rest of retail: Record numbers of bankruptcies and store closures have devastated the retail sector. So why is the beauty market thriving? Will the likes of Sephora and Ulta be able to ward off Amazon? With guests Moj Mahdara, chief executive of Beautycon, and&nbs... by Behind the Money
18 min listen
Tesla’s rough ride: Elon Musk's grand vision for the electric carmaker has drawn dedicated fans and followers. But Tesla has also tested the patience of customers and investors after a hit-and-miss on production targets while burning through cash. What will it take f... by Behind the Money
19 min listen
Coming soon: A weekly podcast from the Financial Times that digs into the big business and financial stories in the news. Behind The Money starts Tuesday, May 1. by Behind the Money
1 min listen
Following the cannabis money trail (encore episode): Medical marijuana is legal in 21 countries. In Canada, residents expect they will be able to buy cannabis from dispensaries and pharmacies across the country later this year. Some analysts have valued the legal business at anywhere between $7bn-$20bn, ... by Behind the Money
20 min listen
Trump, trade and the markets: After a week that began with a tense G7 summit and ended with the US imposing more tariffs on Chinese goods, many expected to see a big slide in financial markets. But stocks remained flat last week. Why aren't investors bracing for rockier times?... by Behind the Money
19 min listen
The future of dealmaking with Saudi Arabia: Some of the world’s most influential financiers and executives have spent the past three years courting Saudi Arabia’s dealmaker-in-chief Mohammed bin Salman and his $300bn state investment fund. But the disappearanc... by Behind the Money
19 min listen
Private equity's debt mountain (encore episode): Private equity has flooded the deal market in recent years, in part due to an era of cheap debt and fund managers on the hunt for greater investment returns. Firms are scooping up stakes in... by Behind the Money
20 min listen
The economic crisis in Argentina explained: After Mauricio Macri came to power in 2015, international investors poured money into Argentina's hundred-year bond with the hopes that the centre-right leader would stabilise the economy after years of disarray. But less than three years later, t... by Behind the Money
18 min listen
Taking a short break: Behind The Money is going on a short hiatus for the next few weeks. We'll be back on Tuesday 31 July with brand new episodes. In the meantime, send us an email to behindthemoney@ft.com if you have any feedback on the series so fa... by Behind the Money
1 min listen
The dark side of fast fashion: Some big name fast fashion retailers are sourcing their inventory closer to home in order to get the latest pieces into the hands of their shoppers fast. But how is it possible such labour intensive production is taking place in one of the most expensi... by Behind the Money
19 min listen
The repo market: A key short term lending market came under strain in September, raising concerns that the Federal Reserve's attempt to unwind post-financial crisis intervention may have gone too far. The FT's Joe Rennison explains what has been going on in t... by Behind the Money
21 min listen
Huawei and the fight for 5G: The arrest of Meng Wanzhou, Huawei's chief financial officer, followed months of mounting scrutiny of the world's biggest telecoms equipment maker. The FT's Nic Fildes explains how Huawei grew to be such a big player, and why western int... by Behind the Money
21 min listen
Following the cannabis money trail: Medical marijuana is legal in 21 countries. In Canada, residents expect they will be able to buy cannabis from dispensaries and pharmacies across the country later this year. Some analysts have valued the legal business at anywhere between $7bn-$20bn, ... by Behind the Money
19 min listen
How WeWork really works: The co-working and office providing company set out to create the office of the future and has caught the attention of big investors, including SoftBank's Vision Fund. Will office subleasing open the door to profit for WeWork? With FT guests Dan T... by Behind the Money
20 min listen
What happened at Qualcomm?: The Trump administration blocked chipmaker Broadcom's bid to acquire rival Qualcomm on the grounds of national security. But how did the San Diego-based company become the target in the first p... by Behind the Money
18 min listen
On the front lines of the crisis: Nick was a regulator at the London Stock Exchange. Julia was an entrepreneur whose home was foreclosed. Ten years on from the collapse of Lehman Brothers we talk to two people with different perspectives on the lessons of the global financial crisis. ... by Behind the Money
24 min listen
Private equity's debt mountain: Private equity has flooded the deal market in recent years, in part due to an era of cheap debt and fund managers on the hunt for greater investment returns. Firms are scooping up stakes in... by Behind the Money
20 min listen
Taking Tesla private: What is behind Elon Musk's plan to take the electric carmaker private, and who will provide the funding? The FT's Arash Massoudi explains the story that has unfolded since the chief executive posted his "funding secured" tweet. Read... by Behind the Money
19 min listen
Khosrowshahi's year at the wheel: A little more than a year ago, Uber's board was in search of a new chief executive. Co-founder Travis Kalanick had resigned from the top job amid allegations of a toxic and sexist company culture, and the board was looking for someone to fix the... by Behind the Money
20 min listen
Purdue Pharma's 'one-two' punch: The name “Sackler” adorns museums and art galleries around the world. But the family name has also become tainted by its association with the US opioid crisis, amid accusations that OxyContin, more than any other drug, is responsible ... by Behind the Money
21 min listen
Digging into student debt: The amount of outstanding student debt in the US has hit a staggering $1.4tn, and many millennials say the education-related debt they've been saddled with has prevented them from doing things like buying a home, getting married and taking career ... by Behind the Money
18 min listen
How Boeing plans to return the Max to the skies: Nearly one year after the grounding of Boeing's 737 Max jet, more than 700 of these planes remain on the ground, with costs to the US manufacturing giant estimated to reach nearly $20bn. The FT's Claire Bushey reports on how... by Behind the Money
25 min listen
The rise and fall of General Electric: GE is one of the greatest names in American business. It was an original member of the Dow Jones Industrial Average, and at its peak the industrial conglomerate had a market capitalisation of nearly $600bn. But after decades of dealmaking, a weakening ... by Behind the Money
22 min listen
China's Didi adds finance to the mix: In 2017, the Chinese ride-hailing app was the highest valued start-up in the world at $56bn. But after a difficult period in 2018 following the murder of two passengers on its platform and a government crackdown, Didi has made a move to diversify by of... by Behind the Money
21 min listen
Investors fear 'peak iPhone': Apple shares have taken a hit this month amid fears that demand for the iPhone has peaked. Tim Bradshaw explains what is worrying investors.   by Behind the Money
21 min listen
Corporate America's new role: The purpose of the US corporation has evolved over time, from Henry Ford's mission to benefit the carmaker's employees to Milton Friedman's essay on shareholder primacy. The FT's US business editor, Andrew Edgecliffe-Johnson, report... by Behind the Money
20 min listen
Warren Buffett's cash dilemma: Over the past 54 years, shares in Berkshire Hathaway have outpaced the broader market. But now the conglomerate is holding onto more than $100bn in cash that it would rather be investing. The FT's Eric Platt guides us through the Berkshire Hathawa... by Behind the Money
27 min listen
IBM's next move: In October, IBM announced it would acquire open source software pioneer Red Hat for $34bn. The deal resonated with Wall Street, but making the two companies work together will be another challenge. The FT’s Richard Waters digs into IBM's history a... by Behind the Money
20 min listen

More Episodes from Behind the Money

Skip carousel

Coming soon: China, the new tech superpower: Reports from the frontlines of China’s march to tech supremacy by Behind the Money
1 min listen
Was the Archegos implosion illegal?: Criminal trial of founder Bill Hwang begins this week by Behind the Money
24 min listen
How shale rewrote the global oil order: What’s keeping oil prices from jumping higher? by Behind the Money
18 min listen
When M&A goes wrong: Examining how the sale of a California supermarket to a private equity firm turned rotten by Behind the Money
21 min listen
Inside the battle for America’s West: The FT’s Oliver Roeder expands on a saga that’s played out since 2021 inside courtrooms and within thousands of pages of legal documents by Behind the Money
24 min listen
Coming soon: The Five Minute Investor from Money Clinic by Behind the Money
1 min listen
Can WeightWatchers survive the Wegovy era?: A weight loss titan fights to stay relevant in the age of GLP-1 drugs by Behind the Money
17 min listen
A surprising winner in the US-China chip wars: How Malaysia is making the most of the rivals’ battle for global tech supremacy by Behind the Money
19 min listen
A radical change for the US Treasury market: Examining the changes sweeping through the world's largest bond market by Behind the Money
16 min listen
Listener mailbag with the Unhedged podcast: Unhedged and Behind the Money answer listener questions about markets and finance by Behind the Money
24 min listen
Are penny stocks getting the memestock treatment?: Why some penny stocks are trading more than shares in Tesla by Behind the Money
17 min listen
How JPMorgan thrived amid a banking crisis: What’s behind the bank’s stellar profits by Behind the Money
18 min listen
Is OpenAI’s business model sustainable?: One of the fastest-growing companies in history faces steep costs by Behind the Money
18 min listen
Hedge fund pioneers face signs of a reckoning: Rising interest rates and a ‘talent war’ are dampening enthusiasm for the multi-manager strategy by Behind the Money
17 min listen
Why Elon Musk is breaking up with Delaware: Delaware has long been the go-to place for companies to incorporate. Can Elon Musk change that? by Behind the Money
16 min listen
Baidu’s ‘do-or-die’ bet on AI: Baidu’s chief executive Robin Li zeroes in on generative AI to turn the business around by Behind the Money
17 min listen
Is this nuclear power’s moment?: Many challenges stand in the way of a ‘nuclear power renaissance’ by Behind the Money
16 min listen
Introducing: Swamp Notes from The FT News Briefing by Behind the Money
1 min listen
BlackRock goes all in on infrastructure: Inside the massive money manager’s ‘transformational’ acquisition by Behind the Money
17 min listen
An IPO drought pushes investors to a murky marketplace: Will the venture secondary market take off in 2024? by Behind the Money
18 min listen
Introducing Untold: The Retreat by Behind the Money
2 min listen
Ozempic’s unconventional origins by Behind the Money
21 min listen
Listener mailbag with Martin Wolf & more by Behind the Money
20 min listen
TED Talks Daily: The next global superpower isn’t who you think: Political scientist Ian Bremmer discusses who runs the world by Behind the Money
22 min listen
Author Amy Edmondson on ‘intelligent failure’: Hear from the winner of the FT and Schroders Business Book of the Year by Behind the Money
31 min listen
The ‘Ponzi scheme’ behind Lebanon’s economic collapse: Inside the scandal plaguing the country’s former central banker, Riad Salameh by Behind the Money
22 min listen
Could COP28 catapult the carbon credit market?: FT climate reporter Kenza Bryan explains the risks that could come with an expanding carbon credit market by Behind the Money
19 min listen
Inside a hedge fund disaster: The Wall Street saga that lost shareholders more than $10 bn by Behind the Money
21 min listen
Best Of: Why companies don't want to list in the UK anymore by Behind the Money
20 min listen
Introducing: Life and Art, from FT Weekend by Behind the Money
1 min listen

Related podcast episodes

Skip carousel

Biotech Buzz: Funding, M&A, and Regulatory Updates in Pharma World by Pharma and BioTech Daily
3 min listen
Pharma and Biotech Daily: Your Essential Dose of Industry News and Exciting Updates! by Pharma and BioTech Daily
3 min listen
Pharma and Biotech Daily: Cyberattacks, Abortion Pills, and Regulatory Uncertainty by Pharma and BioTech Daily
2 min listen
Biopharma Buzz: The Only Podcast for Pharma and Biotech Updates by Pharma and BioTech Daily
4 min listen
Pharma and Biotech Weekly: The Latest in Drug Development, M&A, and Regulatory Updates by Pharma and BioTech Daily
3 min listen
Six biopharma executives consider a tough 2023 and are hopeful for a better 2024: One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee see a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial... by The BioWorld Insider Podcast
17 min listen
As biopharma deals keep pace, M&A volumes languish by The BioWorld Insider Podcast
14 min listen
Parkinson's Disease: Link With Melanoma + Drug Development by Xtalks Life Science Podcast
33 min listen
Pharma and Biotech Daily: Your Morning Dose of Industry Updates by Pharma and BioTech Daily
3 min listen
Pharma and Biotech Daily: AstraZeneca's Cell Therapy Investment, Kyverna's IPO Success, Neurona's Funding Boost, and More! by Pharma and BioTech Daily
2 min listen
$1B+ biopharma deals keep values afloat, even amid muted volume by The BioWorld Insider Podcast
28 min listen
Pharma and Biotech Daily: From Antitrust Probes to Nanoparticle Innovations by Pharma and BioTech Daily
3 min listen
Pharma and Biotech Daily: Stay Informed on Industry Updates and Trends by Pharma and BioTech Daily
2 min listen
August 12th, 2022 by The Top Line
27 min listen
Pharma and Biotech Daily: Your Essential Industry Update in One Line by Pharma and BioTech Daily
3 min listen
Biotech Buzz: IPOs, Cell Therapies, and Industry Insights by Pharma and BioTech Daily
1 min listen
Pharma and Biotech Daily: Navigating the Latest Industry Updates with Precision by Pharma and BioTech Daily
4 min listen
198: PE firm General Catalyst is buying a hospital — here's our take: In this episode, host Rachel Woods and co-host Abby Burns bring back Advisory Board health system expert Vidal Seegobin to interpret the news that venture capitalist firm General Catalyst intends to acquire Summa Health. We've long said “no one is buying hospitals” – have we been wrong? by Radio Advisory
35 min listen
Pharma and Biotech Daily: Keeping You Informed on Industry Updates by Pharma and BioTech Daily
3 min listen
Reviving the stagnant plant based meat market: After a record run of growth, why did plant-based meat sales decline in the U.S.? And what would it take to turn things around? by Catalyst with Shayle Kann
41 min listen
Ailsa Craig: “pharma used to have a worse reputation than tobacco”: We’re all very grateful to the healthcare industry for the amazing work it has done to create vaccines and treatments to help fight the pandemic. But what is the investment outlook now for the companies in the biotech sector?In this interview, Ailsa... by Investors' Chronicle
31 min listen
July 15th, 2022 by The Top Line
30 min listen
April 21, 2023 by The Top Line
22 min listen
Healthcare Industry Insights: Pharma and Biotech Daily Podcast by Pharma and BioTech Daily
1 min listen
Biopharma Buzz: Key Updates in Pharma and Biotech World by Pharma and BioTech Daily
2 min listen
Rising Unemployment, Rising Investor Optimism: More than 5 million more Americans file for unemployment as the monthly total surpasses 22 million. Abbott Labs gets a boost on optimism over its coronavirus testing. Gilead Sciences gets a boost on optimism over its coronavirus treatment. Procter... by Motley Fool Money
39 min listen
Friday, January 4: Traders expect the Federal Reserve to pause future rate rises, Bristol-Myers Squibb's $90bn takeover of Celgene signals a big year for pharma M&A and agricultural researchers discover a genetic breakthrough in crop growth. Then, why EU officia... by FT News Briefing
9 min listen
Another record year for biopharma financings bodes well for 2022 by The BioWorld Insider Podcast
19 min listen
UK's NHS Backs World's Costliest Drug for Treatment of MLD + Report Finds Increase in Pharma Cybersecurity Threats by Xtalks Life Science Podcast
26 min listen
Alex Philippidis Reviews Trends in Biopharma & Biotech Market: Biotech and biopharma companies are in a phase of accelerated growth. Alex Philippidis, a science journalist at Genetic Engineering & Biotechnology News discusses the changing face of big pharma, biotech, and CRISPR gene editing industries, as they raise... by CRISPR Cuts
28 min listen

Discover this podcast and so much more

Pharma raises its bet on biotech

Pharma raises its bet on biotech

Description

Titles in the series (100)

More Episodes from Behind the Money

Related podcast episodes